Recherche dans les collections de brevets nationales et internationales
Certains contenus de cette application ne sont pas disponibles pour le moment.
Si cette situation persiste, veuillez nous contacter àObservations et contact
1. (WO2016170112) CONSERVATION IN VITRO DE CELLULES THÉRAPEUTIQUES
Note: Texte fondé sur des processus automatiques de reconnaissance optique de caractères. Seule la version PDF a une valeur juridique

CLAIMS

1. A method for non-cryogenic in vitro preservation of cells comprising maintaining adherent mesenchymal stem cells (MSC) or adherent MSC-derived cells in suspension in a composition comprising at least 20% v/v human plasma or human serum or a mixture thereof.

2. The method according to claim 1, comprising:

a) providing the composition comprising (i) the MSC or MSC-derived cells and (ii) the human plasma or human serum or the mixture thereof, optionally wherein said providing comprises al) collecting the MSC or MSC-derived cells and a2) suspending the MSC or MSC-derived cells with at least the human plasma or human serum or the mixture thereof; and

b) maintaining the composition, so as to effect preservation of the cells.

3. The method according to any one of claims 1 or 2, wherein the composition is maintained at or below ambient temperature.

4. The method according to any one of claims 1 to 3, wherein the composition is maintained at between about 0.1 °C and ambient temperature.

5. The method according to any one of claims 1 or 2, wherein the composition is maintained at between about 0.1 °C and about 25°C.

6. The method according to any one of claims 1 or 2, wherein the composition is maintained at between about 2°C and about 8°C.

7. The method according to any one of claims 1 to 6, wherein the composition is maintained for at least 24 hours, or for at least 30 hours, or for at least 36 hours, or for at least 42 hours, or for at least 48 hours, or for at least 72 hours, or for at least 96 hours, or for at least 120 hours, or for at least 144 hours, or for at least 168 hours, or for at least 192 hours.

8. The method according to claim 7, wherein the composition is maintained for at least 48 hours, preferably for at least 72 hours, more preferably for at least 96 hours, even more preferably for at least 120 hours, such as for at least 144 hours, or for at least 168 hours, or for at least 192 hours.

9. The method according to any one of claims 1 to 8, wherein the composition is maintained at between about 2°C and about 8°C for at least 48 hours, preferably for at least 72 hours, more preferably for at least 96 hours, even more preferably for at least 120 hours, such as for at least 144 hours, or for at least 168 hours, or for at least 192 hours.

10. The method according to any one of claims 1 to 9, wherein the source of human plasma is fresh plasma, freeze -dried plasma, solvent/detergent-treated plasma, fresh frozen plasma, thawed plasma, or cryoprecipitate, cryosupernatant or plasma concentrate such as concentrate from frozen plasma, or a mixture of any two or more thereof, or wherein the human serum is fresh serum, thawed frozen serum, or serum prepared from plasma, or a mixture of any two or more thereof.

11. The method according to any one of claims 1 to 10, wherein the composition remains liquid all through said maintaining of the composition.

12. The method according to any one of claims 1 to 11, wherein the concentration of the human plasma or human serum or the mixture thereof in the composition is at least 50% v/v, preferably at least 60% v/v, more preferably at least 70% v/v, even more preferably at least 80% v/v, still more preferably at least 90% v/v, yet more preferably at least 99-100% v/v.

13. The method according to any one of claims 1 to 12, wherein the concentration of the MSC or MSC-derived cells in the composition is between about 1 x 104 and about 1 x 1011, or between about 1 x 105 and about 1 x 1010, or between about 1 x 106 and about 1 x 109, or between about 1 x

10 7 and about 1 x 108 , or between about 2 x 107 and about 5 x 107, such as about 2.5 x 107 cells per mL of the composition.

14. The method according to any one of claims 1 to 13, wherein the composition consists essentially of or consists of i) the MSC or MSC-derived cells and ii) the human plasma or human serum or the mixture thereof.

15. The method according to any one of claims 1 to 13, wherein the composition is further supplemented with one or more fractionated components of plasma or serum, preferably wherein the composition is supplemented with human serum albumin (HSA).

16. The method according to any one of claims 1 to 15, wherein the MSC-derived cells comprise osteoprogenitors, osteoblastic cells, osteocytes, chondroblastic cells, chondrocytes, fibroblastic cells, fibroblasts, fibrocytes, tenoblasts, tenocytes, or synoviocytes.

17. The method according to any one of claims 1 to 16, wherein the MSC or MSC-derived cells are human MSC or MSC-derived cells.